epiglucan and Multiple-Myeloma

A 59-year-old patient with multiple myeloma on maintenance chemotherapy presented with fever, weight loss, and night sweats. An F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) computed tomography (CT) showed intra-abdominal lymphadenopathy with a mesenteric mass that led to further workup and diagnosis of histoplamosis. The patient was treated with amphotericin B and subsequently switched to itraconazole. This exemplifies the usefulness of FDG PET CT in diagnosis of infectious complications.

Topics: Amphotericin B; Antifungal Agents; Antineoplastic Agents; beta-Glucans; Colonoscopy; Fever; Fluorodeoxyglucose F18; Gastrointestinal Diseases; Hematopoietic Stem Cell Transplantation; Histoplasma; Histoplasmosis; Humans; Ileum; Intestinal Obstruction; Itraconazole; Lymphadenopathy; Male; Middle Aged; Multiple Myeloma; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Weight Loss

We assessed the performance of galactomannan and (1→3)-β-d-glucan in 29 serum samples from patients with multiple myeloma and Waldenstrom's macroglobulinemia without invasive fungal disease to address issues of false positivity and uninterpretable results previously reported among patients with these conditions. Galactomannan and (1→3)-β-d-glucan assays were not falsely elevated in any patient. (1→3)-β-d-glucan assay results were uninterpretable in 24% of patients. Patients with IgG levels of >2,000 mg/dl had higher odds of uninterpretable (1→3)-β-d-glucan results.

Topics: Adult; Aged; Aged, 80 and over; beta-Glucans; Diagnostic Errors; Female; Galactose; Humans; Male; Mannans; Middle Aged; Multiple Myeloma; Mycoses; Proteoglycans; Serum; Waldenstrom Macroglobulinemia